Cencora (COR) Stock Price, News & Analysis

Company Overview

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers. These services include commercialization support, market access and reimbursement consulting, patient hub and adherence programs, specialty pharmacy management, and clinical support services that help bring specialty and high-cost therapies to market and to patients efficiently.

Cencora operates across multiple geographies with a network of distribution centers, specialty pharmacies and logistics facilities that serve hospitals, health systems, retailers, independent pharmacies, physician practices and manufacturers. The company’s infrastructure and service model are geared toward handling both high-volume commodity products and complex specialty medicines, including oncology, rare disease and biologic therapies.

The company was formed through the rebranding of AmerisourceBergen in 2023 and is headquartered in Conshohocken, Pennsylvania. It is led by Steven H. Collis, who has served as chief executive officer since 2011. Cencora’s business model emphasizes integrated supply chain capabilities and services that support pharmaceutical manufacturers, payers and providers in delivering therapies to patients.

Key Stats

• Today's Range: $266.25 to $272.27
• 50-Day Range: $253.20 to $332.06
• 52-Week Range: $244.82 to $377.54
• Volume: 3.11 million shs
• Average Volume: 2.27 million shs
• Market Capitalization: $52.38 billion
• P/E Ratio: 20.65
• Dividend Yield: 0.89%
• Price Target: $380.25
• Consensus Rating: Moderate Buy

Cencora Stock Analysis - MarketRank™

Cencora scored higher than 97% of companies evaluated by MarketBeat, and ranked 11th out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cencora has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 12 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Cencora has a consensus price target of $380.25, representing about 41.2% upside from its current price of $269.21.

Amount of Analyst Coverage

Cencora has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.68%

Earnings Growth

Earnings for Cencora are expected to grow by 10.68% in the coming year, from $17.79 to $19.69 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cencora is 20.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.88.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cencora is 20.65, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.20.

Price to Earnings Growth Ratio

Cencora has a PEG Ratio of 1.23. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Cencora has a P/B Ratio of 14.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.73% of the float of Cencora has been sold short.

Short Interest Ratio / Days to Cover

Cencora has a short interest ratio ("days to cover") of 1.82, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cencora has recently increased by 1.88%, indicating that investor sentiment is decreasing.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Cencora has a dividend yield of 0.90%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Cencora has been increasing its dividend for 15 years.

Dividend Coverage

The dividend payout ratio of Cencora is 18.40%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Cencora will have a dividend payout ratio of 12.19% next year. This indicates that Cencora will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.69

News Sentiment

Cencora has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Cencora this week, compared to 8 articles on an average week.

Search Interest

18 people have searched for COR on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.

MarketBeat Follows

12 people have added Cencora to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cencora insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.38% of the stock of Cencora is held by insiders.

Percentage Held by Institutions

97.52% of the stock of Cencora is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 3/2 Dividend: 2/13/2026
• Ex-Dividend for 3/2 Dividend: 2/13/2026
• Dividend Payable: 3/02/2026
• Last Earnings: 5/06/2026
• Record date for 6/1 Dividend: 5/15/2026
• Ex-Dividend for 6/1 Dividend: 5/15/2026
• Today: 5/30/2026
• Dividend Payable: 6/01/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Health Care Distributors
• Current Symbol: NYSE:COR
• CIK: 1140859
• Web: www.amerisourcebergen.com
• Phone: (610) 727-7000
• Fax: 800-640-5221
• Employees: 51,000
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Cencora: $380.25
• High Price Target: $440.00
• Low Price Target: $331.00
• Potential Upside/Downside: +41.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $13.04
• Trailing P/E Ratio: 20.65
• Forward P/E Ratio: 15.13
• P/E Growth: 1.23
• Net Income: $1.55 billion
• Net Margins: 0.78%
• Pretax Margin: 1.07%
• Return on Equity: 135.20%
• Return on Assets: 4.20%

Debt

• Debt-to-Equity Ratio: 3.40
• Current Ratio: 0.95
• Quick Ratio: 0.59

Sales & Book Value

• Annual Sales: $321.33 billion
• Price / Sales: 0.16
• Cash Flow: $21.73 per share
• Price / Cash Flow: 12.39
• Book Value: $18.43 per share
• Price / Book: 14.61

Miscellaneous

• Outstanding Shares: 194,560,000
• Free Float: 193,822,000
• Market Cap: $52.38 billion
• Optionable: Optionable
• Beta: 0.64